Literature DB >> 1990058

Antigenic characterization of the nucleoprotein and matrix protein of influenza C virus with monoclonal antibodies.

K Sugawara1, H Nishimura, S Hongo, F Kitame, K Nakamura.   

Abstract

Monoclonal antibodies against the nucleoprotein (NP) and matrix (M) protein of influenza C virus were prepared and characterized. At least two non-overlapping or partially overlapping antigenic sites were delineated on each of the proteins by competitive binding assays. Western blot analysis showed that two antigenic sites on the M protein were highly resistant to conformational changes whereas two sites on NP were sensitive. No antigenic variation was seen in either the NP or the M protein when the reactivity of monoclonal antibodies with 23 different influenza C strains isolated over a 41 year period was studied by radioimmunoprecipitation and enzyme-linked immunosorbent assay. Immunofluorescence analysis with the monoclonal antibodies revealed that both the NP and M proteins migrated to the cell nucleus during the replication cycle of influenza C virus.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1990058     DOI: 10.1099/0022-1317-72-1-103

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  13 in total

1.  Role of the CM2 protein in the influenza C virus replication cycle.

Authors:  Takatoshi Furukawa; Yasushi Muraki; Takeshi Noda; Emi Takashita; Ri Sho; Kanetsu Sugawara; Yoko Matsuzaki; Yoshitaka Shimotai; Seiji Hongo
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

2.  Protective effect of serum antibody on respiratory infection of influenza C virus in rats.

Authors:  K Takiguchi; K Sugawara; S Hongo; H Nishimura; F Kitame; K Nakamura
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

3.  Characterization of a second protein (CM2) encoded by RNA segment 6 of influenza C virus.

Authors:  S Hongo; K Sugawara; Y Muraki; F Kitame; K Nakamura
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

4.  A nuclear export signal in the matrix protein of Influenza A virus is required for efficient virus replication.

Authors:  Shuai Cao; Xiaoling Liu; Maorong Yu; Jing Li; Xiaojuan Jia; Yuhai Bi; Lei Sun; George F Gao; Wenjun Liu
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

5.  Effect of Phosphorylation of CM2 Protein on Influenza C Virus Replication.

Authors:  Takanari Goto; Yoshitaka Shimotai; Yoko Matsuzaki; Yasushi Muraki; Ri Sho; Kanetsu Sugawara; Seiji Hongo
Journal:  J Virol       Date:  2017-10-27       Impact factor: 5.103

6.  Influenza C virus NS1 protein upregulates the splicing of viral mRNAs.

Authors:  Yasushi Muraki; Takatoshi Furukawa; Yoshihiko Kohno; Yoko Matsuzaki; Emi Takashita; Kanetsu Sugawara; Seiji Hongo
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

7.  Influenza C virus CM2 protein is produced from a 374-amino-acid protein (P42) by signal peptidase cleavage.

Authors:  S Hongo; K Sugawara; Y Muraki; Y Matsuzaki; E Takashita; F Kitame; K Nakamura
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

8.  A mutation on influenza C virus M1 protein affects virion morphology by altering the membrane affinity of the protein.

Authors:  Yasushi Muraki; Toshio Murata; Emi Takashita; Yoko Matsuzaki; Kanetsu Sugawara; Seiji Hongo
Journal:  J Virol       Date:  2007-05-30       Impact factor: 5.103

9.  Isolation of a novel swine influenza virus from Oklahoma in 2011 which is distantly related to human influenza C viruses.

Authors:  Ben M Hause; Mariette Ducatez; Emily A Collin; Zhiguang Ran; Runxia Liu; Zizhang Sheng; Anibal Armien; Bryan Kaplan; Suvobrata Chakravarty; Adam D Hoppe; Richard J Webby; Randy R Simonson; Feng Li
Journal:  PLoS Pathog       Date:  2013-02-07       Impact factor: 6.823

10.  Effect of cysteine mutations in the extracellular domain of CM2 on the influenza C virus replication.

Authors:  Yasushi Muraki; Takako Okuwa; Toshiki Himeda; Seiji Hongo; Yoshiro Ohara
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.